Background: Deep venous thromboses (DVT) continue to cause significant morbidity in critically ill patients. Standard prophylaxis for high risk patients includes twice-daily dosing with 30 mg enoxaparin. Despite prophylaxis, DVT rates still exceed 10% to 15%. Anti-Xa levels are used to measure the activity of enoxaparin and 12-hour trough levels Յ0.1 IU/mL have been associated with higher rates of DVT in orthopedic patients. We hypothesized that low Anti-Xa levels would be found in critically ill trauma and surgical patients and that low levels would be associated with higher rates of DVT. Methods: All patients on the surgical intensive care unit (ICU) service were prospectively followed. In the absence of contraindications, patients were given prophylactic enoxaparin and anti-Xa levels were drawn after the third dose. Trough levels Յ0.1 IU/mL were considered low. Screening duplex exams were obtained within 48 hours of admission and then weekly. Patients were excluded if they did not receive a duplex, if they had a prior DVT, or if they lacked correctly timed anti-Xa levels. DVT rates and demographic data were compared between patients with low and normal anti-Xa levels. Results: Data were complete for 54 patients. Eighty-five percent suffered trauma (Injury Severity Score of 25 Ϯ 12) and 74% were male. Overall, 27 patients (50%) had low anti-Xa levels. Patients with low anti-Xa levels had significantly more DVTs than those with normal levels (37% vs. 11%, p ϭ 0.026), despite similar age, body mass index, Injury Severity Score, creatinine clearance, high risk injuries, and ICU/ventilator days. Conclusion: Standard dosing of enoxaparin leads to low anti-Xa levels in half of surgical ICU patients. Low levels are associated with a significant increase in the risk of DVT. These data support future studies using adjusted-dose enoxaparin.
V enous thromboembolic complications (VTE) remain a persistent problem in critically ill trauma and surgical patients. Deep venous thrombosis (DVT) rates range from 13% to 31% in prospectively screened intensive care unit (ICU) patients and up to 70% of severely injured trauma patients who are not receiving prophylaxis. 1, 2 Pulmonary emboli (PEs) occur in ϳ2% of trauma patients 2, 3 and represent the most common cause of preventable hospital deaths. 4 The most recent American College of Chest Physicians Evidence-Based Clinical Practice Guidelines recommend chemical prophylaxis with low-molecular weight heparin (LMWH) in high-risk trauma patients and either LMWH or low-dose unfractionated heparin (LDH) in high-risk surgery patients. [3] [4] [5] Mechanical prophylaxis is also recommended in high-risk patients. Despite prophylaxis, DVT rates up to 44% have been reported, with 6% to 15% being proximal. 3, 5, 6 The pioneering study by Geerts et al. 5 in 1996 demonstrated that prophylactic LMWH was superior to LDH in trauma patients with an Injury Severity Score (ISS) Ͼ9. LMWH was also been shown to be preferred over LDH after spinal cord injury by Green et al. in 1990 7 and in general surgery patients by Nurmohamed et al. in 1995. 8 However, numerous subsequent studies have demonstrated conflicting results with regards to the relative efficacy of LMWH over LDH. 4 In addition, follow-up studies in trauma patients have failed to confirm that LMWH is superior to LDH 9, 10 or that chemical prophylaxis is more effective than mechanical prophylaxis alone. 11 Plasma antifactor Xa levels can be used to assess the systemic effects of LMWH. Previous research involving DVT prophylaxis after hip replacement surgery found that patients with 12-hour trough anti-Xa levels Յ0.1 IU/mL experienced a significantly higher rate of DVTs (15% vs. 6%, p Ͻ 0.05) and levels Ͼ0.2 U/mL were associated with higher rates of wound hematoma formation (25% vs. 5%, p Ͻ 0.01). 12 Currently, it is only recommended to check anti-Xa levels or adjust dosages after LMWH administration in obese, elderly, pediatric, or severe renal impairment patients because of a predictable anticoagulant response in other patient groups. [13] [14] [15] However, it has been recently shown that a broad range of ICU patients experience altered pharmacokinetics and pharmacodynamics of LMWH as evidenced by low trough anti-Xa levels after standard LMWH dosing. 16 -21 This may account for the heterogeneity of results found in previous VTE prevention studies and the persistent occurrence of DVT and PE despite prophylactic measures.
Although there is growing evidence that critically ill trauma and surgical patients are at risk of having low anti-Xa levels, the clinical significance of these levels has not been determined in this population. Before embarking on adjusteddose LMWH studies to achieve improved prevention of VTE, the correlation between the low anti-Xa levels and the occurrence of VTE should be established. We hypothesized that standard, twice-daily dosing of LMWH would lead to low anti-Xa levels in our critically ill trauma and surgical patients and that low levels would be associated with a significant increase in DVTs. We also sought to determine whether risk factors for having low anti-Xa levels after standard LMWH dosing could be identified in our mixed trauma-surgical ICU (SICU).
PATIENTS AND METHODS
All patients being cared for by the SICU service of an university Level I trauma center from January 2008 to June 2009 were prospectively studied. SICU patients were treated according to a preestablished VTE prevention algorithm. This included standard subcutaneous twice-daily LMWH dosing with 30 mg enoxaparin (Sanofi-aventis, Bridgewater, NJ) as soon as acute blood loss was stabilized, unless contraindicated for any of the following reasons: renal impairment, future bleeding risk, early mobilization (not high risk for VTE), or thrombocytopenia (Ͻ100,000/L). The exact start date was as per the discretion of the primary attending surgeon. Sequential compression devices were applied to the lower extremities bilaterally on admission to either the operating room or SICU. When lower extremity injuries were present, sequential compression devices were placed on any two available upper or lower extremities. Routine screening bilateral upper and lower extremity Duplex ultrasound examinations were obtained within 48 hours of admission and weekly thereafter. PEs were diagnosed by computed tomography angiography when clinically suspected. Peak (drawn 4 hours after the third dose) and trough (drawn 1 hour before fourth dose) plasma anti-Xa levels were ordered on all patients receiving prophylactic LMWH and were run on a chromogenic assay the day they were drawn. Trough anti-Xa values Յ0.1 IU/mL were considered "low levels" and those Ͼ0.1 IU/mL were "normal."
Data regarding age, gender, height, weight, body mass index, medical history, specific injuries, reason for ICU admission, ICU length of stay, and ventilator days were collected as were other potential risk factors for altered LMWH pharmacokinetics: creatinine clearance (CrCl) and the presence of either the systemic inflammatory response syndrome (SIRS) or sepsis the day anti-Xa levels were drawn. The criteria for SIRS were the presence of at least two of the following: temperature Ͻ36°C or Ͼ38°C, respiratory rate Ͼ20 breaths per minute or PCO 2 Ͻ32 mm Hg, heart rate Ͼ90 beats per minute, or a white blood cell count Ͻ4,000/L or Ͼ12,000/L. Sepsis was defined as SIRS with a presumed or documented infection. 22 CrCl was calculated as ([140 Ϫ age {years}] ϫ weight {kg}/[72 ϫ serum Cr {mg/dL}]), multiplied by 0.85 for women.
The primary outcome measure was the occurrence of any VTE: a PE or proximal DVT in the lower or upper extremities (central to the elbow or knee). Patients were excluded if they did not receive a Duplex scan after initiating LMWH prophylaxis and obtaining anti-Xa levels, if a VTE occurred before initiating LMWH, if they did not receive at least three doses of LMWH, if they received any dosing strategy other than 30 mg twice daily, or if they lacked correctly timed anti-Xa levels.
To determine whether low anti-Xa levels were significantly associated with higher VTE rates, patient characteristics, risk factors for DVT, and proportions of patients with a VTE in the low and normal anti-Xa level groups were compared. Risk factors for DVT that were included in the analysis were determined a priori: age, ISS, intracranial hemorrhage/contusion, spinal cord injury, spine fracture, pelvic fracture, extremity fractures, and any laparotomy for trauma or general surgical reasons.
To identify risk factors for having low anti-Xa levels, patients who had correctly timed trough levels, but who were previously excluded because of a lack of a screening duplex or a VTE before starting LMWH, were included in a secondary analysis. Patient demographics, CrCl, ISS, total intravenous fluids given during the first 48 hours of admission, ICU and ventilator days, the presence of SIRS/SEPSIS, and peak anti-Xa levels were compared between groups.
Because the final study population only represented a minority of those cared for by our SICU service during the study period, patient demographics, injury patterns, and outcomes were compared between the included and excluded patients. For statistical analyses, the Pearson 2 or Fisher's exact test was used for categorical variables and the independent Student's t test was used for continuous ones. A p value Ͻ0.05 was used to determine statistical significance. Statistical Package for the Social Sciences software version 17.0 (SPSS, Chicago, IL) was used for the analyses, and our study was approved by the Institutional Review Board of the University of California, Irvine.
RESULTS
Eight hundred ninety-two patients were cared for by the SICU service during the study period. One hundred seventyfour received prophylactic LMWH, whereas the other 716 either received therapeutic LMWH for an early VTE or did not receive prophylactic LMWH because of high risk for bleeding, renal insufficiency, low platelet count, or low risk for VTE. Of those patients receiving LMWH, 54 had correctly timed peak and trough anti-Xa levels and no other exclusion criteria (Fig. 1) .
The 54 included patients had a mean Ϯ SD age of 42 years Ϯ 21 years, 74% were men, and 85% suffered trauma (80% blunt with an ISS of 25 Ϯ 12). The 54 patients had 16 ICU days Ϯ 10 ICU days and 10 ventilator days Ϯ 8 ventilator days. Fourteen patients (26%) had any VTE, 13 (24%) with a proximal DVT, and 1 (2%) with a PE. Location of DVT was available for 12 patients: 5 (42%) lower and 10 (83%) upper, with 3 (25%) having both. DVTs occurred 15 days Ϯ 10 days postinjury (range. 1-32) and after 2 Ϯ 1.4 sets of Duplex examinations (range, 1-5). The one PE that occurred after SICU admission occurred on postinjury day 9; this patient did not have a positive Duplex examination.
Twenty-seven (50%) patients had low trough anti-Xa levels. Patients with low trough anti-Xa levels had significantly more DVTs than those with normal levels (37% vs. 11%, p ϭ 0.026, Fig. 2 ). They also had significantly lower peak anti-Xa levels (0.17 IU/mL Ϯ 0.1 IU/mL vs. 0.27 IU/mL Ϯ 0.1 IU/mL, p Ͻ 0.001). Both groups had similar demographics, reason for SICU admission, risk factors for DVT, and ICU/ventilator days; the only exception being a higher proportion of patients with normal levels having a closed head injury (Table 1) . Of note, peak anti-Xa levels were not different in those with and without a DVT (0.23 IU/mL Ϯ 0.12 IU/mL vs. 0.23 IU/mL Ϯ 0.1 IU/mL).
The secondary analysis of risk factors for having low trough anti-Xa levels included 86 patients and could not identify any patient characteristics as significant predictors other than having lower peak anti-Xa levels ( Table 2 ). Given that one would have to draw anti-Xa levels to know the peak was low, this was not considered a useful predictor. There was also a trend toward more SIRS or sepsis in the group with normal trough levels and a higher mean weight in the group with low trough levels.
The details of the comparison between the included and excluded patients are illustrated in Table 3 . Included patients were significantly younger, were more likely to have suffered a traumatic injury, and had greater severity of illness as evidenced by a higher ISS, longer ICU and ventilator days, and more SIRS and sepsis. They were also more likely to have had a laparotomy. The included patient population had more VTE, specifically lower extremity DVTs.
DISCUSSION
Despite standard mechanical and chemical prophylaxis, proximal DVTs occur in up to 15% of critically ill trauma and surgical patients, 3, 5, 6 and studies regarding the relative efficacy of LMWH, LDH, and mechanical compression have revealed mixed results. The altered pharmacodynamics and pharmacokinetics of ICU patients may account for this heterogeneity and the persistent occurrence of VTE in all reported series. Consistent with published guidelines by the American College of Chest Physicians 4 and the Eastern Association for the Surgery of Trauma, 23 LMWH is the preferred method of chemical prophylaxis against VTE in our SICU. Plasma anti-Xa levels can be used as a biological marker of LMWH activity. Although routine monitoring of anti-Xa activity in clinically stable adults with uncomplicated disease is not recommended, the optimal dosage of LMWH has not been established for patients with altered physiology or at the extremes of weight and age, 13 The relationship between low trough anti-Xa levels and DVT rates. Trough anti-Xa levels were drawn within 1 hour of the fourth dose of LMWH. Low levels were defined as being Յ0.1 IU/mL and normal levels were Ͼ0.1 IU/mL. The DVT rates between the two groups were compared using the Fisher's exact test. have demonstrated low anti-Xa levels during critical illness. 16, 17, 19, 24 The objectives of this study were to determine how common low anti-Xa levels are, if low anti-Xa levels correlate with an increased risk for DVT, and to identify risk factors for having low anti-Xa levels in our critically ill trauma and surgical patient population. We found that low anti-Xa levels occurred in 50% of our patients, that they were associated with a more than threefold increase in DVTs, and that there were no identifiable risk factors for low trough anti-Xa levels other than lower peak anti-Xa levels. In 1989, Levine et al. 12 tested the relationship of low anti-Xa levels with the incidence of wound hematomas and DVTs in patients receiving once-daily LMWH dosing after hip replacement. He found that 12-hour trough anti-Xa levels Ͼ0.2 IU/mL were associated with significantly more wound hematomas (25% vs. 5%) and that levels Յ0.1 IU/mL were associated with significantly more DVTs (15% vs. 6%). These findings have been cited by numerous authors and have served as the reference range for appropriate prophylaxis throughout the medical literature: 0.1 IU/mL to 0.2 IU/mL. Our study is the first to correlate anti-Xa levels after twicedaily prophylactic LMWH with DVT occurrence in critically ill trauma and surgical patients. We did not specifically examine the occurrence of wound hematomas, as not all of our patients had surgical incisions when DVT prophylaxis was initiated. Many risk factors have been shown to be related to low anti-Xa levels in previous studies: weight, body mass index, CrCl, vasopressor use, multiple organ dysfunction, peripheral edema, and critical illness. 16,17,19,24 -26 In a series of 17 SICU patients receiving 40 mg of enoxaparin once daily for VTE prophylaxis, Rutherford et al. 16 found that 88% had trough anti-Xa levels Ͻ0.1 IU/mL. Similarly, Jochberger et al. found that only 6% of critically ill patients receiving once-daily dosing of 3,000 IU certoparin (Novartis, Basel, Switzerland), another LMWH, had appropriate anti-Xa levels after 12 hours and 24 hours. Consequently, the authors changed their dosing interval to twice daily and found that the proportion of patients that had appropriate prophylactic anti-Xa levels increased to 27% to 30%, but the majority still did not. 24 Although our results did not identify any specific patient characteristics that were significantly associated with low trough anti-Xa levels, they did add to the growing body of evidence demonstrating a high prevalence of low levels after both once-and twice-daily LMWH dosing in the ICU.
Because individual responses to fixed-dose LDH also vary greatly, Leyvraz et al. 27 randomized total hip replacement patients to standard (3,500 IU every 8 hours) versus adjusted-dose LDH to achieve an activated partial thromboplastin time in the high normal range. The adjusted-dose group required more LDH, had higher activated partial thromboplastin time levels, and experienced significantly fewer proximal DVTs (5% vs. 32%, p Ͻ 0.003). Adjusteddose LDH was not associated with increased blood transfusions, drops in hemoglobin levels, or wound hematomas.
Van et al. 6 have proposed a trial of adjusted-dose LMWH using thromboelastography (TEG). In their study of 61 SICU patients, the authors found that time to clot formation (TEG R value) was significantly shorter in patients who developed a DVT. Peak anti-Xa levels were not found to be different in patients with and without a DVT in this study, but trough levels were not drawn. The methodology of this study differs from ours in two other notable ways: several dosing strategies for LMWH were included and the exact timing of Duplex surveillance in relation to SICU admission and the drawing of blood samples was not specified. Although the authors concluded that TEG is superior to plasma anti-Xa levels for differentiating LMWH-treated patients who subsequently develop a DVT, their results are not in opposition with ours, in that, we also found that peak anti-Xa levels were not different in patients with and without DVTs. If trough levels had been drawn and similar methodologies had been used, a better comparison between TEG and anti-Xa levels could have been performed. Nonetheless, the strategy to identify patients with low anticoagulant activity after standard LMWH dosing and adjust dosages accordingly is one that should be pursued.
The strengths of this study are that it was prospective and a formal clinical algorithm was used for all patients being cared for by a single service. The structured Duplex surveillance protocol combined with strict inclusion criteria should minimize potential bias. The limitations of the study are rooted in the same qualities as the strengths; although Duplex examinations are the most commonly used diagnostic examination, they are not as sensitive as fibrinogen uptake testing or venography. 1 Similarly, many patients were excluded to maintain the quality of the data, but this limited our sample size and, potentially, the generalizability of the results; although there were 174 patients who received prophylactic LMWH, 12 were excluded because of receiving a dose other than 30 mg twice daily, 76 were excluded for not having correctly timed anti-Xa levels, and 32 were excluded as a result of either having a VTE before receiving LMWH, not having a Duplex after obtaining levels, or having a preadmission history of VTE. This left 54 patients (53% of those receiving prophylactic LMWH) in the primary analysis. Being that most published series either do not require or do not specify such a strict set of inclusion criteria for documenting the presence or absence of a DVT both before and after initiating LMWH, obtaining 54 patients with complete data in 18 months is not significantly less than what others have achieved in similar studies. 6 Having a funded research staff available 24 hours a day to ensure compliance with obtaining correctly timed anti-Xa levels would have increased the number of patients that we included and this will be necessary for future, prospective studies.
In addition, a large number of our SICU patients (80%) did not receive LMWH because of clinically appropriate contraindications, further impacting the applicability of our results. The accepted reasons for not receiving prophylactic LMWH included bleeding risk, renal insufficiency, low platelet count, and early mobilization with a low risk for DVT. The neurosurgery department at our institution recommends either subcutaneous heparin or no chemical prophylaxis at all for patients with intracranial hemorrhage or unstable cervical spine fractures. These patients, combined with those with solid organ injuries, make up the majority of those who had a significant bleeding risk. Despite these exclusions, the patients who were ultimately included tended to be a more severely injured and critically ill subset of the general SICU population with a high incidence of VTE (26%). Although we have attempted to be transparent and explicit with our patient selection process, the possibility of a hidden bias should be considered when interpreting our results.
Recommended VTE prophylaxis strategies do not adequately prevent DVT or PE in high-risk trauma and surgical patients, and further research is needed. 28 Being that neither this study nor the one by Van et al. were able to identify any significant patient characteristics that predict having low anticoagulant activity after receiving standard doses of prophylactic LMWH and that half of SICU patients have low anti-Xa levels, it appears that all critically ill trauma and surgical patients need to be screened to determine who might benefit from adjusted-dose LMWH. Future studies that examine the ability to raise low anti-Xa or TEG values with adjusted-dose LMWH, the safety of the higher doses that will be required, and whether or not increased levels will result in fewer VTE should be considered. The first is that our ability to eliminate thromboembolic disease is very imperfect and probably impossible due to inadequate understanding of some basic biology and conflicting opinions of various providers of when the risk-benefit ratio of starting anticoagulation can occur.
Unfortunately, also, outside forces will always consider our care substandard since it seems to be the elimination of ALL thromboembolic disease has become a national health care obsession.
Second is the detection and treatment of venous thromboembolic disease is labor-intensive, as evidenced by their study and finding a lot of them late in their hospital course. Again, this activity is also poorly compensated by those same outside nefarious forces that want us to eliminate the disease.
But, lastly and most importantly, it's just another example that dosage of drugs to trauma patients is similar to pantyhose in that one size does not fit all and probably we need to adjust their medication to a greater extent.
The authors suggest that monitoring Anti-Xa levels are the way to go and I have no problem with the general conclusion but I do have some questions about the study.
From your graph and from your paper when you cull down and exclude various groups your study population is actually 6 percent of all people admitted to your unit and only 30 percent of the patients underwent VTE prophylaxis.
Comparing the groups you excluded and you tried to match them between the excluded and not excluded but why are only 30 percent of your ICU patients getting VTE prophylaxis? Are the remaining patients who sustained TBI and that your neurosurgeons don't let you anticoagulate them forever?
The Journal of TRAUMA ® Injury, Infection, and Critical Care • Volume 68, Number 4, April 2010 Anti-Xa Levels and DVT I also know running unfunded clinical trials are hard but you had about a 46 percent missed time levels that were drawn. This seems to be a little large. And do you think that played a lot of role in your bias here in some of your study?
In the manuscript you described that the patients who had a laparotomy required, had a greater incidence of lower trough levels. Could this be a marker for bigger fluid shifts?
Did you look at other markers of shock, lactate, 24-hour fluid, 48-hour fluid balance, blood requirements to see if those are the groups who end up with lower trough levels? Again, that's been shown in some of the antibiotic ICU studies.
And, lastly, where are you going now? Are you suggesting that this is the way to go? It's a concept that clearly appears worthy of multi-center clinical trials as we are all struggling with this issue and we still end up with people with venous thromboembolic disease.
It might also help our neurosurgical colleagues, most of which never want us to ever allow anybody to ever be anticoagulated.
I want to thank the organization once again for the privilege of discussing this paper and congratulations to the authors on a very good job.
Dr. Darren J. Malinoski (Irvine, California): Doctor Livingston, thank you for the comments and questions. In terms of the study population only being 6 percent of all the patients seen by our service over the study period and only 30 percent of our patients receiving prophylaxis, the easier question is why only 30 percent received prophylaxis with low-molecular weight heparin. Yes, head injury was a big part of it and our neurosurgeons prefer subcutaneous-heparin or no prophylaxis at all. Other patients that did not receive propylaxis with low-molecular weight heparin were those with an increased bleeding risk and those who left the ICU early and did not need prophylaxis. When you look at other series that have recently been published, I don't think that number is that dissimilar.
In terms of only 54 patients, or 6% of all the patients treated by the SICU service, being included, I think that has to do with our strict inclusion criteria that required a duplex within 48 hours of ICU admission and after obtaining correctly timed anti-Xa levels. Not all studies have that strict criteria for proving that you don't have a DVT at the end of your prophylaxis. In addition, 47 percent of patients who received prophylactic low-molecular weight heparin had missed or improperly-timed anti-Xa levels; it is always amazing to me how hard it is to get prospective studies done and when levels are drawn at night and the study personnel aren't around, that is a challenge. It is something that we deal with all the time. In terms of how those patients differed from the included ones, we compared their rates of DVT and they did not differ.
In terms of laparotomies, the manuscript demonstrates that a greater percentage of the included patients had a laparotomy compared to the excluded patients. There was not a significant relationship between laparotomies and low anti-Xa levels, however. The only data that we collected that are associated with shock are total intravenous fluids given in the first 48 hours and we will include that in the revised manuscript.
As for where we go from here, similar to what Doctor Schreiber's group from OHSU proposed in the paper they presented here last year on TEG's and LMWH, we intend to do prospective studies and we would love to collaborate. The key steps for a prospective trial would be to check levels on all patients, increase dosing in patients with low levels and an acceptable bleeding risk, check to see if levels actually increase, monitor for bleeding complications with higher levels, and determine if raising levels lowers DVT rates. Thank you.
Dr. Krishnan Raghavendran (Ann Arbor, Michigan): It's very simplistic to think that the dosage of administration is the only factor that designates the efficacy of enoxaparin. It's administered subcutaneously.
You talked about weight but you haven't talked about overall fluid balance. Was there an amount of fluid that was given to these patients much more than the ones that turned out to have DVT?
The other aspect is AT3 levels. Did you check Antithrombin 3 levels? If the Antithrombin 3 levels are really low then it is very unlikely that your enoxaparin is going to have efficacy. Thank you.
Dr. Darren J. Malinoski (Irvine, California): In terms of fluid balance, we did not have their net balance on the day levels were checked, nor did we account for edema being present which has been shown in other studies. And we also did not measure Antithrombin 3 levels.
Dr. Gage M. Ochsner, Jr. (Savannah, Georgia): I'd like to compliment you on a very difficult study that you did.
My question is, how much does it cost for your institution to get an Anti-X level? And what is your turn-around time? Because for us it takes over 24 hours to get that back.
So I mean do you get it turned around quickly? And it's an expensive test at my institution, also. So going forward we really need a lot of good evidence to justify that cost.
Dr. Darren J. Malinoski (Irvine, California): I think that the study cost institutionally would be about $10. The patient cost I think is about $80 or $90 in terms of what shows up on a bill.
The turn-around time at our institution is the same day but they tend to run them at one point in time so it would be several hours depending on when you sent the lab in. Thank you.
